Nancy Andrews, MD, PhD
Nanaline H. Duke Professor of Pediatrics
Professor of Pharmacology & Cancer Biology
Nancy Andrews, M.D, Ph.D., is the vice chancellor for academic affairs and dean of the Duke University School of Medicine. She is also a professor in the departments of Pediatrics and Pharmacology & Cancer Biology.
Dr. Andrews received her B.S. and M.S. degrees in molecular biophysics and biochemistry from Yale University, her Ph.D. in biology from MIT, and her medical degree from Harvard Medical School. She completed her internship and residency in pediatrics at Children's Hospital Boston, and her hematology/oncology fellowship at Children's Hospital and the Dana-Farber Cancer Institute.
After she completed her training, Andrews stayed on at Harvard and Children's Hospital Boston, rising through the academic ranks to become the George Richards Minot Professor of Pediatrics at Harvard, senior associate in medicine at the Children's Hospital Boston, and a distinguished physician of the Dana-Farber Cancer Institute.
She served as an attending physician in hematology and oncology at Children's Hospital until 2003. She was director of the Harvard-MIT MD-PhD program from 1999 to 2003 and dean for basic sciences and graduate studies at Harvard Medical School from 2003 to 2007.
Andrews has maintained an active NIH-funded research laboratory studying mouse models of human diseases. She was a Howard Hughes Medical Institute Investigator from 1993 to 2006. She has authored well over 100 peer-reviewed articles and 16 book chapters and has received many awards and honors for her research, including membership in the Institute of Medicine of the National Academies and in the American Academy of Arts and Sciences. She is a past president of the American Society of Clinical Investigation. She joined the BWF Board in October 2011.
Emery N. Brown, MD, PhD
Warren M. Zapol Professor of Anaesthesia
Harvard Medical School/Massachusetts General Hospital
Edward Hood Taplin Professor of Medical Engineering and Computational Neuroscience Massachusetts Institute of Technology
Emery N. Brown is the Warren M. Zapol Professor of Anaesthesia at Harvard Medical School and Massachusetts General Hospital (MGH), the Edward Hood Taplin Professor of Medical Engineering and Computational Neuroscience at the Massachusetts Institute of Technology (MIT) and an anesthesiologist at MGH.
Dr. Brown received his B.A. (magna cum laude) in Applied Mathematics from Harvard College, his M.A. in statistics from Harvard University, his M.D. (magna cum laude) from Harvard Medical School and a Ph.D. in statistics from Harvard University. He is an anesthesiologist-statistician whose methodology research develops signal processing algorithms to characterize how the brain represents and transmits information. His experimental research has made important conceptual and experimental contributions to understanding how anesthetic drugs act in the brain to create the state of general anesthesia.
Dr. Brown has served on the BWF Careers at the Scientific Interface Advisory Committee, the NIH Brain Initiative Working Group, the NIH National Advisory Neurological Disorders, and Stroke Council and the Board of Mathematical Sciences and Its Applications of the National Research Council. He is currently a member of the NSF Mathematical and Physical Sciences Advisory Committee, the Board of Directors of the International Anesthesia Research Society, the NIH Council of Councils, the Council of the American Academy of Arts and Sciences and the Scientific Advisory Committee of CURE Epilepsy.
Dr. Brown is the recipient of an NIH Director’s Pioneer Award, the Jerome Sacks Award from the National Institute of Statistical Sciences and an NIH Director’s Transformative Research Award. Dr. Brown is a fellow of the IEEE, the American Statistical Association, the American Association for the Advancement of Science and the American Academy of Arts and Sciences. He is a member of the Institute of Medicine, the National Academy of Sciences and the National Academy of Engineering. He joined the BWF Board in October 2012.
John E. Burris, PhD
Burroughs Wellcome Fund
John E. Burris became president of the Burroughs Wellcome Fund in July 2008. He is the former president of Beloit College. Prior to his appointment at Beloit in 2000, Dr. Burris served for eight years as director and CEO of the Marine Biological Laboratory (MBL) in Woods Hole, Mass. From 1984 to 1992 he was at the National Research Council/National Academies where he served as the executive director of the Commission on Life Sciences.
A native of Wisconsin, he received an A.B. in biology from Harvard University in 1971, attended the University of Wisconsin-Madison in an M.D.-Ph.D. program, and received a Ph.D. in marine biology from the Scripps Institution of Oceanography at the University of California-San Diego in 1976. A professor of biology at the Pennsylvania State University from 1976 to 1985, he held an adjunct appointment there until coming to Beloit. His research interests were in the areas of marine and terrestrial plant physiology and ecology.
He has served as president of the American Institute of Biological Sciences and is or has been a member of a number of distinguished scientific boards and advisory committees including the Grass Foundation, the Stazione Zoologica “Anton Dohrn” in Naples, Italy, the American Association for the Advancement of Science, and the Radiation Effects Research Foundation in Hiroshima, Japan. He has also served as a consultant to the National Conference of Catholic Bishops' Committee on Science and Human Values.
Terence S. Dermody, MD
Vira I. Heinz Professor and Chair of Pediatrics
Professor of Microbiology and Molecular Genetics
University of Pittsburgh School of Medicine
Physician-in-Chief and Scientific Director
Children’s Hospital of Pittsburgh of UPMC
Dr. Terence S. Dermody is the Vira I. Heinz Professor and Chair of Pediatrics at the University of Pittsburgh School of Medicine and Physician-in-Chief and Scientific Director at Children’s Hospital of Pittsburgh of UPMC. He also is Professor of Microbiology and Molecular Genetics at the University of Pittsburgh School of Medicine.
Dr. Dermody received his B.S. degree from Cornell University and his M.D. degree from Columbia University. He completed an internal medicine residency at Presbyterian Hospital in New York and fellowships in infectious diseases and molecular virology at Brigham and Women’s Hospital and Harvard Medical School. Prior to moving to Pittsburgh, Dr. Dermody was Dorothy Overall Wells Professor of Pediatrics and Director of the Medical Scientist Training Program and Division of Pediatric Infectious Diseases at Vanderbilt University School of Medicine.
Dr. Dermody is a virologist with interests in viral pathogenesis and vaccine development. Most of his research has focused on reovirus, an important experimental model for studies of viral encephalitis in the young, and chikungunya virus, an emerging mosquito-borne virus that causes epidemics of fever and arthritis. His research contributions have enhanced an understanding of how these viruses enter into host cells and cause organ-specific disease. He has published more than 220 articles, reviews, chapters, and editorials and has been recognized for his research accomplishments by the Vanderbilt Ernest W. Goodpasture Faculty Research Award, an NIH MERIT Award, and the American Society for Microbiology D. C. White Research and Mentoring Award.
Dr. Dermody is a member of the American Academy of Microbiology, American Pediatrics Society, American Society for Clinical Investigation, Association of American Physicians, and Society for Pediatric Research and a fellow of the American Association for the Advancement of Science. He is a past president of the American Society for Virology, past chair of the AAMC GREAT Group M.D.-Ph.D. Section Steering Committee, and current chair of the Virology Division of the International Union of Microbiological Societies. Dr. Dermody is an editor for the Journal of Virology and mBio and an associate editor for the Annual Review of Virology. He became a member of the Board of Directors of the Burroughs Wellcome Fund in 2015.
Brian Druker, MD
Director, Knight Cancer Institute at Oregon Health & Science University
JELD-WEN Chair of Leukemia Research
Investigator, Howard Hughes Medical Institute
Brian Druker, MD, revolutionized the treatment of cancer through research that resulted in the first drug to target the molecular defect of cancer while leaving healthy cells unharmed. Marketed under the name Gleevec®, his discovery turned a once-fatal cancer, chronic myeloid leukemia, into a manageable condition.
Treatment with Gleevec received FDA approval in record time, was featured on the cover of Time magazine, and established Druker as a pioneer in the field of precision medicine. Most important, his discovery became a new proof of principal for targeted therapies, spurring the development of more than 50 similar precision therapies for other cancers.
Druker now is applying key principles of precision medicine to early detection. Earlier detection of lethal cancers represents the greatest opportunity to increase cancer survival rates. Thanks to $1 billion in philanthropic funding, Druker is developing a large-scale early detection program that builds upon the scientific strengths of OHSU’s Knight Cancer Institute.
Druker has been recognized with numerous awards, including the Warren Alpert Prize from Harvard Medical School, the Lasker-DeBakey Award for Clinical Medical Research, the Japan Prize in Healthcare and Medical Technology, and most recently, the 2018 Tang Prize in Biopharmaceutical Science. He has been elected to the National Academy of Medicine, the National Academy of Sciences and the American Academy of Arts and Sciences.
Wendell Lim, PhD
Professor and chair, Department of Cellular and Molecular Pharmacology
University of California - San Francisco
Howard Hughes Medical Institute Investigator
director, UCSF Center for Systems & Synthetic Biology
Wendell Lim, PhD, is interested in understanding how genetically encoded molecular programs can yield the remarkable behaviors observed in biological organisms, at multiple scales. He received his undergraduate degree at Harvard University and a doctoral degree at MIT, as well as completing a postdoctoral fellowship at Yale University. Now chair and professor of cellular and molecular pharmacology at UC San Francisco, Lim began his research career as a biophysical chemist and structural biologist studying problems such as the evolutionary optimization of enzymes, how protein structure is encoded in sequence, and the determinants of protein-protein interaction specificity. His research has gradually shifted towards utilizing this mechanistic understanding of molecules as a foundation to study how systems of interacting molecules assemble to yield cellular or organismal signaling behaviors – complex behaviors in both space and time. His lab is interested in both the fundamental principles governing these molecular programs, as well as the way such programs have evolved. How to identify the most relevant functional modules at various scales of biology is an ongoing but fascinating challenge. We have also become interested in using synthetic biology and our growing understanding of molecular networks to engineer cells with novel behaviors, such as therapeutic immune cells programmed to recognize and treat cancer or other diseases. A Howard Hughes Medical Institute Investigator, Lim is director of the UCSF Center for Systems and Synthetic Biology and is the scientific founder of Cell Design Labs, a company pioneering advanced cell therapies. Dr. Lim joined the Burroughs Wellcome Fund Board of Directors in October 2018.
Kelsey Martin, MD, PhD
Dean for the David Geffen School of Medicine
Professor of Biological Chemistry and Psychiatry and Biobehavioral Sciences
University of California-Los Angeles
Dr. Kelsey Martin is the Dean for the David Geffen School of Medicine at UCLA and a Professor in the Departments of Biological Chemistry and Psychiatry and Biobehavioral Sciences. Outside UCLA, In addition to being a Senior Fellow at the Howard Hughes Medical Institute Janelia Research Campus, Dr. Martin serves on the editorial board of Cell, the board of directors for the Burroughs Wellcome Fund, the selection committee of the McKnight Scholar Awards and the board of directors of the McKnight Endowment Fund for Neuroscience. Dr. Martin served as co-director of the UCLA-Caltech Medical Scientist Training Program from 2005-2013, Chair of the Department of Biological Chemistry from 2010-2015, Chair of the Neuroscience Research Theme Committee from 2013-2015 and Chair of the David Geffen School of Medicine Basic Science Chairs from 2012-2015. She was named Executive Vice Dean and Associate Vice Chancellor at the Geffen School of Medicine earlier this year.
Dr. Martin received her B.A. in English and American Language and Literature at Harvard University. After serving as a Peace Corps volunteer in the Democratic Republic of Congo, she entered the MD-PhD program at Yale University where she studied influenza virus-host cell interactions in the laboratory of Dr. Ari Helenius, receiving her PhD degree in Molecular Biophysics and Biochemistry and her MD degree in 1992. She went on to complete her postdoctoral training in neurobiology with Dr. Eric Kandel at Columbia University and joined the UCLA faculty in 1999.
Dr. Martin directs a productive research laboratory focused on understanding how experience changes connectivity in the brain to store long-term memories. While many aspects of brain circuitry are hard-wired, it is also dynamic: the connections between neurons in the brain change with experience to store information, and in this way, nature and nurture combine to define our identities. Conversely, experiences that produce maladaptive changes in brain circuitry underlie many neuropsychiatric disorders, and age-related decreases in brain plasticity contribute to age-related memory disorders such as Alzheimer’s disease. Long-lasting changes in brain connectivity require new gene expression, and Dr. Martin has discovered a role for specific signaling molecules that travel from stimulated synapses to the nucleus to change the transcription of DNA to RNA. Her research also has highlighted a central role for the localization of RNAs to synapses, where their synthesis into protein is regulated by neuronal activity, and that the process of local protein synthesis is likely to play a particularly important role in autism spectrum disorders.
She joined the BWF Board of Directors in October 2015.
Roderick R. McInnes, MD, PhD
Director of the Lady Davis Institute of the Jewish General Hospital
Canada Research Chair in Neurogenetics
Professor of Genetics and of Biochemistry
Roderick R. McInnes is the Director of the Lady Davis Institute of the Jewish General Hospital, Canada Research Chair in Neurogenetics, and Professor of Genetics and of Biochemistry at McGill University, where he has succeeded Charles Scriver as the Alva Chair in Human Genetics. Until recently, he was a University Professor of the University of Toronto and Senior Scientist at the Hospital for Sick Children. Dr. McInnes received his undergraduate and medical degrees from Dalhousie University, and his Ph.D. from McGill. Previously he was the Head of the Program in Developmental Biology at the Research Institute of the Hospital for Sick Children, an International Research Scholar of the Howard Hughes Medical Institute and, from 2000-2010, the inaugural Scientific Director of the Institute of Genetics of CIHR. He has made important contributions to the understanding of the molecular basis of retinal and eye development, and to the identification of genes and processes associated with inherited retinal degenerations. Recently, he and collaborators identified an important protein, Neto1, required for learning and memory, and established that it is possible to correct an inherited learning defect in mice with a drug, a finding with important implications for human learning disability. He is a coauthor of the 5th, 6th and 7th editions of Thompson and Thompson’s Genetics in Medicine, and of the CIHR Guidebook for New Principal Investigators. Amongst other honors, Dr. McInnes is a Fellow of the Royal Society of Canada and the Canadian Academy of Health Sciences and was the recipient of an honorary Doctor of Laws from Dalhousie University in 2007. He was appointed to the Order of Ontario in 2008, and a member of the Order of Canada in 2009. In 2010, Dr. McInnes was the President of the American Society of Human Genetics.
Lauretta (Retz) Reeves, CFA, AWMA
International Portfolio Manager
Islamorada Investment Management
Retz Reeves is the international equities portfolio manager at Islamorada Investment Management (IIM) and utilizes a value-based approach. Ms. Reeves joined IIM in 2013. She has served as a portfolio manager and Co-Chief Investment Officer of the Value Strategy at Hansberger Global Investors (HGI). Before HGI, Ms. Reeves was a portfolio manager and Senior Vice President with Franklin Templeton Investments. She is a CFA® Charter Holder and a member of the CFA Institute and The CFA Society of South Florida. Also, she holds the designation of Accredited Wealth Management Advisor (SM) (“AWMA”) from the College of Financial Planning. She received a BBA from Florida International University with High Honors and an MBA from Nova Southeastern University. She is a member of the Baptist Hospital Foundation Founders’ society and the Upper Keys Century Business and Professional Women. Ms. Reeves also serves as a mentor for Take Stock in Children.
Christine Seidman, MD
T.W. Smith Professor of Medicine & Genetics
Investigator of Howard Hughes Medical Institute
Director, Brigham & Women's Cardiovascular Genetics Center
Christine Seidman, MD is the Thomas W. Smith Professor of Medicine and Genetics at Harvard Medical School and Brigham and Women’s Hospital. She is an Investigator of the Howard Hughes Medical Institute. She was an undergraduate at Harvard College and received a M.D. from George Washington University School of Medicine. After clinical training in Internal Medicine at John Hopkins Hospital Seidman received subspecialty training in cardiology at the Massachusetts General Hospital.
Seidman practices at the Brigham and Women’s Hospital, where she is the founding Director of the BWH Cardiovascular Genetics Center. Composed of a multidisciplinary team of physicians and scientists, the BWH Cardiovascular Genetics Center provides unparalleled care to patients with cardiomyopathies and their families. Through her translation of basic science discoveries, the BWH Cardiovascular Genetics Center has transformed the clinical diagnosis and management of cardiomyopathies and is defining innovative treatment strategies.
Seidman directs a basic research program that focuses on the discovery of genes, mutations, and mechanisms for human heart muscle disorders, particularly cardiomyopathies and congenital heart defects. Translation of these fundamental discoveries has enabled gene-based diagnosis and novel therapeutic targets. Her accomplishments have garnered many honors, including the Fondation Lefoulon-Delande Le Grande Prix for Cardiovascular Research awarded by the Academie de Science, - Institut de France, Distinguished Scientist Award of the American Heart Association, Fellow of the American Academy of Arts and Sciences, and membership in the National Academy of Medicine and the National Academy of Sciences. Dr. Seidman is also a former president of the Association of American Physicians.
Jenny Ting, PhD
William Rand Kenan Professor of Genetics
Immunology Program Leader, Lineberger Comprehensive Cancer Center
Director, UNC Center for Translational Immunology
Co-Director, Institute of Inflammatory Disease
University of North Carolina-Chapel Hill
Dr. Jenny Ting received her Ph.D. in Microbiology and Immunology from Northwestern University in Chicago, IL and postdoctoral training at the University of Southern California and Duke University. She joined the faculty at the University of North Carolina, Chapel Hill as an Assistant Professor and has been there since that time. Currently, she is a William Rand Kenan Professor of Genetics and the UNC Lineberger Comprehensive Cancer Center’s Immunology Program Leader. She is also the Director of the UNC Center for Translational Immunology and the co-Director of the Institute of Inflammatory Diseases.
From 2008 to 2014, she served as the co-Director of the Southeast Regional Center for Excellence in Emerging Infections and Biodefense (SERCEB). She is currently the Program Director of an NIAID-funded Center for Translational Research, NIAID-funded Center for Immune-mediated Viral Control, a National Multiple Sclerosis Society (NMSS) funded Collaborative Multiple Sclerosis Center and an NIH training grant. She has trained more than 90 postdoctoral fellows and students who have gone on to successful scientific careers ranging from deanship, chairmanship, professors and industrial leaders.
Nationally, Dr. Ting has served on multiple NIH advisory boards, as well as committees for the NMSS, Burroughs Wellcome Fund, and American Asthma Foundation. She has been awarded the American Society of Microbiology Award for Outstanding Contributions to the Field of Immunology and Immunity and selected as the 2013 American Association of Immunology prestigious Life Technologies Awardee. She is an elected member of the Academia Sinica in Taiwan and the American Association of Immunologists council.
She has pioneered new areas of innate immunity, most notably reporting the first study describing the entire human NOD-like receptor family and continued to be a leader in this field. Her work combines fundamental innate immunology with molecular biology and she has reported extensively on the impact of innate immunity in infection, autoimmunity, cancer, microbiome composition and metabolic disorders. She has published over 280 articles, many in top journals. She joined the Fund's Board of Directors in February 2017.
Michael J. Welsh, MD (Chair)
Howard Hughes Medical Institute Investigator
Roy J. Carver Biomedical Research Chair in Internal Medicine and Molecular Physiology and Biophysics
Director, Cystic Fibrosis Research Center
Director, Institute for Biomedical Discovery
University of Iowa
Dr. Welsh is a Howard Hughes Medical Institute Investigator and Roy J. Carver Biomedical Research Chair in Internal Medicine and Molecular Physiology and Biophysics, Professor of Neurosurgery, Director of the University of Iowa Cystic Fibrosis Research Center, and Director of the University of Iowa Institute for Biomedical Discovery at the Roy J. and Lucille A. Carver College of Medicine of the University of Iowa. He earned his M.D. degree from the University of Iowa College of Medicine, where he completed his residency. He held clinical and research fellowships in pulmonary disease at the University of California, San Francisco, and did postgraduate research in physiology and cell biology at the University of Texas, Houston. He then returned to the rolling hills of Iowa, where he has restored the native tall grass prairie. Dr. Welsh has served as president of the American Society for Clinical Investigation and president of the Association of American Physicians. His clinical activities are focused on pulmonary diseases.
Honorary Board Member
Philip R. Tracy
Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P.
Mr. Tracy received his undergraduate degree from the University of Nebraska and law degree from George Washington University. He joined Burroughs Wellcome Co. in 1974 as assistant general counsel, and he served as the company's president and the chief executive officer from 1989 until its sale to Glaxo in 1995. Mr. Tracy currently is associated with the North Carolina-based law firm of Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. and is a Venture Partner with InterSouth Partners, an early stage Venture Fund located in Durham, North Carolina. He serves on the board of directors of several companies and non-profit organizations. Mr. Tracy served on the BWF board from 1989-1996 and again from 2001-2008.